Novasep targets US clients with new API kilo scale and synthesis lab

By Dan Stanton

- Last updated on GMT

iStock/Michael Warren
iStock/Michael Warren

Related tags Chemistry

Novasep has expanded its kilogram scale fine chemical offering through a new synthesis facility at its site in Pennsylvania.

According to Andrew Brennan, general manager at Novasep’s US operations, Novasep will be able to offer US drug developers preclinical scales of “any fine chemicals whether they are advanced intermediates or active ingredients”​ from the newly completed synthesis laboratory and kilo lab at the Boothwyn, Pennsylvania site.

“We use chemistry in this lab as upstream, combined with purification downstream steps,”​ Brennan told in-Pharmatechnologist.com.

“The facility is equipped with jacketed reactors ranging from 100mL to 50L in size and with a 35L filter dryer for isolation of kilogram quantities of compound.”

The privately owned French manufacturing services provider said the expansion is part of its 'back to basics' strategic plan, bringing more localised development services to the US pharma market, and would also serve as a regional base for Novasep’s complete portfolio of preparative chromatography technologies.

The project was first announced in January​, and is a boost for the firm’s North American presence which has been hit by Celladon ending a contract last year​, as well as through Novasep’s divestment of Pharmachem in 2014.

The unit had been acquired by Novasep in 2007​, and was responsible at one time of generating around 40% of Novasep’s earnings through the supply of the active ingredient Tenofovir, sold to a single customer.

But with the expansion, Brennan said: “We are already speaking with customers on specific projects for the production of first kgs of early stage drug substance.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...